Grufity logoGrufity logo

Jaguar Health Inc Stock Research

JAGX

4.99USD+0.04(+0.81%)Delayedas of 25 Jan 2023, 03:52 pm

Market Summary

USD4.99+0.04
Delayedas of 25 Jan 2023, 03:52 pm
0.81%

JAGX Stock Price

JAGX RSI Chart

JAGX Valuation

Market Cap

7.7M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

1.95

EV/EBITDA

0.07

Price/Free Cashflow

-0.22

JAGX Price/Sales (Trailing)

JAGX Profitability

Return on Equity

-1.5K%

Return on Assets

-106.23%

Free Cashflow Yield

-462.43%

JAGX Fundamentals

JAGX Revenue

JAGX Earnings

Earnings (TTM)

-54.5M

Earnings Y/Y

-3.42%

Earnings Q/Q

-34.28%

Price Action

52 Week Range

0.086.15
(Low)(High)

Last 7 days

5280.4%

Last 30 days

5274.6%

Last 90 days

3335.1%

Trailing 12 Months

532.5%

JAGX Financial Health

Current Ratio

0.94

JAGX Investor Care

Shares Dilution (1Y)

132.03%

Diluted EPS (TTM)

-71.25

Peers (Alternatives to Jaguar Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
442.3B
96.0B
-5.17% 5.99%
23.09
4.61
5.02% 7.14%
308.2B
29.2B
-5.85% 46.05%
51.09
10.54
5.34% 1.02%
278.4B
59.0B
-2.99% 42.09%
18.24
4.72
27.84% 112.03%
252.2B
99.9B
-13.74% -10.43%
8.47
2.53
45.01% 53.21%
155.8B
46.7B
-0.75% 18.09%
23.33
3.33
2.79% 223.53%
MID-CAP
5.0B
4.4B
10.99% -2.60%
-46.61
1.14
1.80% 57.67%
2.2B
659.0M
10.52% 42.11%
58.22
3.33
16.78% -53.92%
SMALL-CAP
1.9B
613.6M
11.47% -46.75%
-3.76
3.11
37.73% -7.19%
1.5B
3.1M
16.69% 58.71%
-4.91
486.39
-77.09% -12.24%
1.3B
-
18.45% -62.70%
-0.44
1.95
-4.11% -144.36%
1.1B
23.5M
8.75% 61.26%
-13.48
47.07
243.57% -1.04%
953.4M
112.7M
-3.54% -28.57%
-4.26
8.46
45.53% 40.26%
902.9M
-
-6.12% -22.22%
2.7
2.34
10.49% -16.07%
300.3M
49.7M
46.44% -30.92%
-5.06
6.04
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Jaguar Health

Income Statement (Last 12 Months)
Description(%) Q/Q2020Q42020Q32020Q22020Q12019Q4
Revenue12.9%9,385,0008,316,0006,516,0005,055,0005,775,000
EBITDA Margin6.8%-3.12-3.35---
EBT Margin3.4%-3.60-3.73---
Net Income Margin3.4%-3.60-3.73---
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets2.8%5150535359
  Current Assets7.9%2523282824
    Cash Equivalents17.2%119171712
  Inventory-2.1%77555
  Net PPE-1.9%11111
Liabilities1.2%4847454138
  Current Liabilities17.7%2723191512
Shareholder's Equity30.5%4381222
  Retained Earnings-5.1%-259.40-246.80-237.48-219.49-205.20
  Additional Paid-In Capital5.4%263250246231227
Accumulated Depreciation3.4%00000
Shares Outstanding33.5%1111-
Minority Interest-217.1%-0.05000-
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations2.5%-35,604.00-36,507.00-35,957.00-34,970.00-30,108.00
  Share Based Compensation-9.7%3,9634,3874,4033,9743,472
Cashflow From InvestingInfinity%20,8440-6.00-20,956.00-
Cashflow From Financing65.6%24,66414,89021,21943,93751,618
* denotes actual numbers (not divided by Thousands)

Risks for JAGX

What is the probability of a big loss on JAGX?

100%


Probability that Jaguar Health stock will be more than 20% underwater in next one year

100%


Probability that Jaguar Health stock will be more than 30% underwater in next one year.

100%


Probability that Jaguar Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JAGX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Jaguar Health was unfortunately bought at previous high price.

Drawdowns

Returns for JAGX

Cumulative Returns on JAGX

-65.9%


7-Year Cumulative Returns

-59.0%


5-Year Cumulative Returns

29.1%


3-Year Cumulative Returns

What are the long-term rolling returns for JAGX?

FIve years rolling returns for Jaguar Health.

Annualized Returns

Which funds bought or sold JAGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-23
Moisand Fitzgerald Tamayo, LLC
new
-
9
9
-%
2023-01-13
Merit Financial Group, LLC
unchanged
-
-2,480
2,520
-%
2022-11-15
JANE STREET GROUP, LLC
new
-
3,000
3,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-15
STATE STREET CORP
unchanged
-
-19,000
22,000
-%
2022-11-14
Stonebridge Capital Advisors LLC
unchanged
-
-
-
-%
2022-11-14
ADVISOR GROUP HOLDINGS, INC.
reduced
-82.25
-
-
-%
2022-11-14
Atria Wealth Solutions, Inc.
unchanged
-
-
3,000
-%
2022-11-14
COMMONWEALTH EQUITY SERVICES, LLC
new
-
3,000
3,000
-%
2022-11-14
WELLS FARGO & COMPANY/MN
reduced
-0.43
-
-
-%

1–10 of 34

Latest Funds Activity

Are funds buying JAGX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own JAGX
No. of Funds

Jaguar Health News

InvestorsObserver

Is Jaguar Health Inc (JAGX) a Loser in the Healthcare Sector?.

InvestorsObserver,
3 hours ago

InvestorPlace

InvestorsObserver

InvestorsObserver

Why Are There So Many Flight Delays Today?.

InvestorsObserver,
14 days ago

Schedule 13G FIlings of Jaguar Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 26, 2022
streeterville capital llc
9.75%
11,500,000
SC 13G
May 10, 2022
mailman joshua
11.1%
8,614,138
SC 13G
Jan 11, 2022
oasis capital, llc
9.99%
4,604,484
SC 13G
Feb 12, 2021
sagard capital partners, l.p.
2.8%
1,910,043
SC 13G/A
Feb 11, 2021
ionic ventures, llc
0%
0
SC 13G/A
Jan 25, 2021
oasis capital, llc
9.99%
6,874,665
SC 13G
Nov 04, 2020
iliad research & trading, l.p.
7.88%
4,750,000
SC 13G
Sep 25, 2020
chicago venture partners, l.p.
8.28%
3,333,333
SC 13G
Sep 11, 2020
sagard capital partners, l.p.
6.1%
2,476,974
SC 13G
Jul 07, 2020
oasis capital, llc
9.99%
1,849,468
SC 13G

JAGX Fair Value

Recent SEC filings of Jaguar Health

View All Filings
Date Filed Form Type Document
Jan 23, 2023
8-K
Current Report
Jan 06, 2023
8-K
Current Report
Jan 03, 2023
4
Insider Trading
Dec 30, 2022
8-K
Current Report
Dec 28, 2022
4
Insider Trading
Dec 28, 2022
4
Insider Trading
Dec 28, 2022
4
Insider Trading
Dec 28, 2022
4
Insider Trading
Dec 28, 2022
4
Insider Trading
Dec 16, 2022
DEFR14A
DEFR14A

Latest Insider Trading transactions for JAGX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-31
Wolin Jonathan S.
bought
9.51
0.03
317
chief of staff, cco & gc
2022-05-18
Siegel Jonathan B.
acquired
-
-
12,133
-
2022-05-18
MICEK JOHN
acquired
-
-
12,133
-
2022-05-18
Divis Gregory J
acquired
-
-
12,133
-
2022-05-18
BOCHNOWSKI JAMES J
acquired
-
-
13,133
-
2022-04-05
Lizak Carol R.
acquired
-
-
4,513
chief financial officer
2022-04-05
Wolin Jonathan S.
acquired
-
-
6,666
chief of staff, cco & gc
2022-04-05
Chaturvedi Pravin R
acquired
-
-
3,333
chief scientific officer
2022-04-05
CONTE LISA A
acquired
-
-
45,000
ceo and president
2022-04-05
King Steven R.
acquired
-
-
13,333
chief of sustainable supply

1–10 of 16

Lisa A. Conte
50
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

JAGX Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses    
Cost of product revenue$ 613,000$ 617,000$ 1,524,000$ 1,864,000
Research and development5,940,0003,312,00013,336,0009,597,000
Sales and marketing2,109,0002,261,0007,089,0006,596,000
General and administrative4,384,0003,969,00014,876,00012,450,000
Series 3 warrants inducement expense   1,462,000
ELOC warrants inducement expense   172,000
Total operating expenses13,046,00010,159,00036,825,00032,141,000
Loss from operations(9,896,000)(9,529,000)(28,129,000)(29,886,000)
Interest expense(2,731,000)(2,078,000)(10,089,000)(5,988,000)
Loss on extinguishment of debt  (2,187,000)(753,000)
Change in fair value of financial instruments and hybrid instrument designated at Fair Value Option176,000(565,000)652,000(1,639,000)
Other expense, net(158,000)(20,000)(410,000)(16,000)
Loss before income tax(12,609,000)(12,192,000)(40,163,000)(38,282,000)
Income tax expense
Net loss and comprehensive loss(12,609,000)(12,192,000)(40,163,000)(38,282,000)
Net loss attributable to noncontrolling interest(89,000) (290,000) 
Net loss attributable to common shareholders(12,520,000)(12,192,000)(39,873,000)(38,282,000)
Net loss attributable to common shareholders (diluted)$ (12,520,000)$ (12,192,000)$ (39,873,000)$ (38,282,000)
Net loss per share, basic$ (0.12)$ (0.27)$ (0.49)$ (0.87)
Net loss per share, diluted$ (0.12)$ (0.27)$ (0.49)$ (0.87)
Weighted-average common shares outstanding, basic106,362,17845,840,26281,657,06144,167,885
Weighted-average common shares outstanding, diluted106,362,17845,840,26281,657,06144,167,885
Product revenue    
Revenue    
Total revenue$ 3,150,000$ 630,000$ 8,696,000$ 2,255,000

JAGX Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash$ 10,561,000$ 17,051,000
Accounts receivable1,825,0001,709,000
Other receivable634,000435,000
Inventory6,601,0004,900,000
Prepaid expenses and other current assets5,587,0004,339,000
Total current assets25,208,00028,434,000
Property and equipment, net572,000650,000
Operating lease - right-of-use asset1,104,0001,084,000
Intangible assets, net22,561,00022,651,000
Other assets1,842,000446,000
Total assets51,287,00053,265,000
Current liabilities:  
Accounts payable6,285,0004,929,000
Accrued liabilities8,504,0007,117,000
Warrant liability 1,000
Operating lease liability, current418,000240,000
Notes payable, current11,737,0003,184,000
Total current liabilities26,944,00015,471,000
Operating lease liability, net of current portion738,000919,000
Notes payable, net of discount, net of current portion (includes hybrid instrument designated at Fair Value Option amounting to $7.2 million and $7.8 million as of September 30, 2022 and December 31, 2021, respectively)20,006,00025,022,000
Total liabilities47,688,00041,412,000
Commitments and contingencies (See Note 7)
Stockholders' equity  
Additional paid-in capital263,001,000231,100,000
Noncontrolling interest(48,000)242,000
Accumulated deficit(259,367,000)(219,494,000)
Total stockholders' equity3,599,00011,853,000
Total liabilities and stockholders' equity51,287,00053,265,000
Series D perpetual preferred stock  
Current liabilities:  
Series D perpetual preferred stock: $0.0001 par value; 977,300 shares authorized at September 30, 2022 and December 31, 2021; zero shares issued and outstanding at September 30, 2022 and December 31, 2021
Series B-2 Preferred Stock  
Stockholders' equity  
Preferred stock value
Series C perpetual preferred stock  
Stockholders' equity  
Preferred stock value
Common stock - voting  
Stockholders' equity  
Common stock value13,0005,000
Common stock - non-voting  
Stockholders' equity  
Common stock value